Form 4: Arteris Inc. VP Sells Shares Under 10b5-1 Plan

Arteris, Inc. VP and General Counsel Paul L. Alpern sold a total of 6,000 shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Paul L. Alpern, VP and General Counsel of Arteris, Inc., executed a series of stock sales on July 6, 2026.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on February 23, 2026.
• A total of 6,000 shares of common stock were sold across three transactions.
• The sales generated proceeds totaling approximately $207,000, based on weighted average sale prices.
• Following these sales, Alpern beneficially owns 70,733 shares of Arteris, Inc. common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as having a slightly negative sentiment due to the significant sale of shares by a key executive, despite being executed under a 10b5-1 plan.

Negatives

• A significant number of shares (6,000) were sold by a key executive, which could be perceived negatively by the market, although conducted under a pre-established plan.

Risks

• The sale of a substantial number of shares by a high-ranking executive, even under a 10b5-1 plan, may raise concerns among investors about insider confidence in the company's future prospects.
• The weighted average sale prices indicate a range of selling prices, suggesting potential market fluctuations during the transaction period.

Future Outlook

The filing itself does not contain forward-looking statements or guidance regarding the company's future performance. It solely reports on past transactions by an executive.

Industry Context

StockSavvy.ai notes that Form 4 filings, particularly those involving sales by senior executives, are closely watched by the market. While a 10b5-1 plan provides a defense against insider trading allegations, significant sales can still influence investor sentiment, especially in the semiconductor IP sector where Arteris operates.

Corporate Governance

Stakeholder Impact

• Shareholders: May interpret the executive's stock sale as a potential signal of reduced confidence, despite the 10b5-1 plan, potentially impacting short-term share price sentiment.
• Employees: Similar to shareholders, employees holding stock options or shares may be influenced by executive trading activity.
• Management: Reinforces the importance of compliance with SEC regulations regarding insider trading and the use of 10b5-1 plans.

Next Steps

• The reporting person will continue to hold the remaining 70,733 shares of common stock.
• Future transactions under the 10b5-1 plan, if any, will be reported on subsequent Form 4 filings.

Key Dates

Recommendation

The filing reports a stock sale by an executive under a 10b5-1 plan. While such sales can create short-term negative sentiment, the use of a pre-arranged plan mitigates concerns about insider knowledge. Without further information on the company's performance or future prospects, a 'hold' recommendation is prudent, suggesting investors monitor future filings and company performance.

Keywords

Arteris Inc., Form 4, SEC Filing, Insider Trading, Stock Sale, 10b5-1 Plan, Paul L. Alpern, VP and General Counsel, Common Stock, Beneficial Ownership